Halozyme(HALO) - 2025 Q4 - Annual Results

Exhibit 99.1 Expands Drug Delivery Opportunity with Acquisition of Surf Bio and its Hyperconcentration Technology Conference Call Scheduled Today at 5:30am PT/8:30am ET SAN DIEGO, January 28, 2026 -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today provided a business update, including providing preliminary unaudited 2025 revenue estimates and raising full year 2026 and multi-year financial guidance. The Company also announced it acquired Surf Bio, Inc. ("Surf Bio"), a biopharm ...